Russia's Rusnano Licenses Six Cancer Drugs Of U.K.'s Lipoxen
This article was originally published in PharmAsia News
Executive Summary
Russia's state-owned Russian Corporation of Nanotechnologies has obtained the licenses for pre-trial stages of six drug candidates from U.K.-based Lipoxen, a biopharmaceutical company